微生物菌群与抗肿瘤药物疗效相关性的研究进展  

Research progress in the correlation between microbiota and the efficacy of anti-tumor drugs

作　　者：雷宇[1] 吴琼[1] 梁雪红 廖柳风(综述) 万瑞融(审校)[2] LEI Yu;WU Qiong;LIANG Xue-hong(Drug Clinical Trial Institution, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, China)

机构地区：[1]广西医科大学附属肿瘤医院药物临床试验机构,南宁530021 [2]广西医科大学第一附属医院药学部,南宁530021

出　　处：《中国临床新医学》2020年第9期949-953,共5页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

基　　金：广西卫健委科研课题(编号:Z20200390);广西壮族自治区中医药管理局科研课题(编号:GZZC2020232)。

摘　　要：抗肿瘤药物耐药是导致肿瘤治疗失败的重要原因,其机制及逆转对策至今仍没有彻底解决。近年来,肿瘤伴生的微生物菌群导致耐药的观点逐步被证实。该文就微生物菌群与化疗药物、免疫治疗药物、靶向药物的疗效相关性及耐药逆转的研究进展进行综述。The resistance of tumor cells to anti-tumor drugs is an important cause of treatment failure,and its mechanisms and reversal strategies have not been completely solved up to now.In recent years,the idea that tumor associated microbiota leads to drug resistance has been gradually confirmed.In this paper,the research progress on the correlation between microbiota and the efficacy of chemotherapy drugs,immunotherapy drugs and targeted drugs,and the reversal of drug resistance are reviewed.

关 键 词：微生物菌群 抗肿瘤药物 耐药 相关性 

分 类 号：R730.3[医药卫生—肿瘤]